Liraglutide-associated acute pancreatitis. (Q53660617)

17 May 2018

title

Liraglutide-associated acute pancreatitis. (English)

1 reference

17 May 2018

1 reference

Emily Knezevich

1

1 reference

17 May 2018

Theresa Crnic

series ordinal

2

1 reference

17 May 2018

Scott Kershaw

series ordinal

3

1 reference

17 May 2018

Andjela Drincic

series ordinal

4

1 reference

17 May 2018

publication date

1 March 2012

1 reference

17 May 2018

American Journal of Health-System Pharmacy

published in

1 reference

17 May 2018

volume

69

1 reference

17 May 2018

issue

5

1 reference

17 May 2018

page(s)

386-389

1 reference

17 May 2018

Liraglutide in clinical practice: dosing, safety and efficacy

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Biology of incretins: GLP-1 and GIP

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Association of pancreatitis with glucagon-like peptide-1 agonist use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Acute pancreatitis associated with liraglutide.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

A method for estimating the probability of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Drug-induced pancreatitis : incidence, management and prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110221

31 March 2020

Identifiers

DOI

10.2146/AJHP110221

1 reference

17 May 2018

1 reference

17 May 2018